The largest study to date to analyse millions of both genetic and patient records on the long-term health conditions of later life has identified opportunities for new ways to prevent and treat multiple overlapping conditions.
Currently, nine million people in the UK live with two or more long-term conditions at the same time – known as multimorbidity. Their treatment accounts for half of the NHS budget.
Led by the University of Exeter Medical School and funded by the Medical Research Council and the National Institute for Health and Care Research, the GEMINI study looked at both genetics and clinical information from more than three million people in the UK and Spain.
Published today in eBioMedicine research has identified genetic overlaps in 72 long-term health conditions associated with ageing, to identify where specific genes are linked to two or more conditions. With more than 2,500 combinations of conditions analysed, the programme aims to unlock cases where a drug or prevention strategies can prevent or delay the onset of multimorbidity. It also revealed genetic connections that explain why certain conditions may be more likely to co-occur in the same patient.
The research comes after the Government’s Chief Scientific Advisor Professor Chris Whitty highlighted improving the treatment of people with one or more long term conditions – known as multimorbidity – as a key priority for research .
Dr Joao Delgado , at the University of Exeter Medical School led the research. He said: “Overlapping long-term conditions have a huge impact on the lives of millions of people and are difficult and costly to treat. For the first time, we’ve combined analysis of both genetics and clinical records on a massive scale, in a new and robust approach to identify where genes play a critical role in more than one condition. We’re now working to drill down into specifics combination of conditions, and expect to reveal drugs or lifestyle changes that already work for treating existing conditions that can be repurposed to prevent multimorbidity, with promising results. For example, we identified the role of treatable conditions, such as B12 deficiency and iron deficiency anaemia in the development of multimorbidity. This will lead to a more personalised approach to prevention and treatment in multimorbidity.”
Co –author Professor Jane Masol i, of the University of Exeter Medical School, said: “A known problem in treating overlapping health conditions is that clinical services and guidelines largely address single disease groups and not the bigger picture. Studying multiple conditions is really complex and until now research has also focussed on one condition at a time. This research, provides a platform for researching what causes overlapping health conditions, and will have major benefits for rapidly progressing medical understanding to ultimately improve people’s lives. Treating people in a more personalised way, as a whole person rather than by single disease, is likely to deliver better quality for people living with multiple conditions, and reduce the burden on health services.”
The paper is entitled ‘A systematic analysis of the contribution of genetics to multimorbidity and comparisons with primary care data ’, and is published in eBioMedicine . The research was supported by the NIHR Exeter Biomedical Research Centre and the Applied Research Collaboration South West Peninsula (PenARC).
ENDS
About the University of Exeter
The University of Exeter is a Russell Group university that combines world-class research with high levels of student satisfaction. Exeter has over 30,000 students and sits within the Top 15 universities in The Complete University Guide 2025, and tenth in the world in the Times Higher Education (THE) Impact Rankings. In the last Research Excellence Framework (REF, 2021), more than 99% of our research were rated as being of international quality, and our world-leading research impact has grown by 72% since 2014, more than any other Russell Group university.
For further information:
University of Exeter
Press Office
+44 (0)1392 722405 or 722062
EBioMedicine
Systematic review
Not applicable
A systematic analysis of the contribution of genetics to multimorbidity and comparisons with primary care data
6-Feb-2025